$Faraday Future Intelligent Electric Inc. (FFAI.US)$
Faraday Future Announces First FX 6 Prototype Mules Have Arrived at its Los Angeles Headquarters; Will Begin U.S. Product Development and Testing Focusing on ADAS
Thursday, 20th March at 8:50 am
The arrival demonstrates the Company's commitment to the mass market AIEV segment and progress of the Faraday (FX) strategy in the U.S.
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ("FF", "Faraday Future", or the "Company"), a California...

$Primega Group (PGHL.US)$
im very lucky buy at $10😇

Updated on October 15
Semiconductor company $ASML Holding (ASML.US)$ experienced its largest drop in 26 years on October 15 after reporting only about half the orders that analysts had anticipated from chipmakers, signaling a significant slowdown for this key industry player, according to Bloomberg.
The disappointing results were further exacerbated by the company accidentally releasing its earnings report a day early. This news prompted a wid...

$Faraday Future Intelligent Electric Inc. (FFIE.US)$
3 times circuit breaker😶‍🌫️

$Faraday Future Intelligent Electric Inc. (FFIE.US)$ Monday open $20/share

$Faraday Future Intelligent Electric Inc. (FFIE.US)$
Faraday Future Reports Financial Results for Second Quarter 2024 and Announces Timing for Earnings Call
Positive
Operating expenses decreased to $29.9 million from $49.4 million year-over-year
Loss from operations improved to $50.6 million from $56.0 million year-over-year
Cash used in operating activities reduced to $29.1 million in H1 2024 from $160.7 million in the prior year period
Raised approximately $15.5 million through converti...

$Atara Biotherapeutics (ATRA.US)$
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3...